Logo image of AKBA

AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis

NASDAQ:AKBA - US00972D1054 - Common Stock

3.01 USD
-0.08 (-2.59%)
Last: 8/27/2025, 8:00:01 PM
3.0394 USD
+0.03 (+0.98%)
After Hours: 8/27/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, AKBA scores 3 out of 10 in our fundamental rating. AKBA was compared to 547 industry peers in the Biotechnology industry. While AKBA is still in line with the averages on profitability rating, there are concerns on its financial health. While showing a medium growth rate, AKBA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

AKBA had negative earnings in the past year.
In the past year AKBA has reported a negative cash flow from operations.
In the past 5 years AKBA always reported negative net income.
In the past 5 years AKBA always reported negative operating cash flow.
AKBA Yearly Net Income VS EBIT VS OCF VS FCFAKBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

AKBA has a better Return On Assets (-10.56%) than 83.18% of its industry peers.
The Return On Equity of AKBA (-124.84%) is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 1.39%, AKBA belongs to the top of the industry, outperforming 91.04% of the companies in the same industry.
Industry RankSector Rank
ROA -10.56%
ROE -124.84%
ROIC 1.39%
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKBA Yearly ROA, ROE, ROICAKBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

With an excellent Operating Margin value of 1.96%, AKBA belongs to the best of the industry, outperforming 91.04% of the companies in the same industry.
AKBA's Gross Margin of 83.22% is amongst the best of the industry. AKBA outperforms 86.65% of its industry peers.
AKBA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.96%
PM (TTM) N/A
GM 83.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
AKBA Yearly Profit, Operating, Gross MarginsAKBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

AKBA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
AKBA has more shares outstanding than it did 1 year ago.
AKBA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AKBA is higher compared to a year ago.
AKBA Yearly Shares OutstandingAKBA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AKBA Yearly Total Debt VS Total AssetsAKBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -4.19, we must say that AKBA is in the distress zone and has some risk of bankruptcy.
AKBA has a Altman-Z score (-4.19) which is comparable to the rest of the industry.
AKBA has a Debt/Equity ratio of 1.61. This is a high value indicating a heavy dependency on external financing.
AKBA has a Debt to Equity ratio of 1.61. This is in the lower half of the industry: AKBA underperforms 79.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Altman-Z -4.19
ROIC/WACC0.14
WACC9.96%
AKBA Yearly LT Debt VS Equity VS FCFAKBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

AKBA has a Current Ratio of 1.98. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
AKBA's Current ratio of 1.98 is on the low side compared to the rest of the industry. AKBA is outperformed by 74.59% of its industry peers.
A Quick Ratio of 1.84 indicates that AKBA should not have too much problems paying its short term obligations.
AKBA has a Quick ratio of 1.84. This is in the lower half of the industry: AKBA underperforms 75.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.84
AKBA Yearly Current Assets VS Current LiabilitesAKBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

AKBA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.05%, which is quite good.
Looking at the last year, AKBA shows a quite strong growth in Revenue. The Revenue has grown by 16.79% in the last year.
Measured over the past years, AKBA shows a very negative growth in Revenue. The Revenue has been decreasing by -13.72% on average per year.
EPS 1Y (TTM)19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)16.79%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%43.13%

3.2 Future

AKBA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.81% yearly.
The Revenue is expected to grow by 26.47% on average over the next years. This is a very strong growth
EPS Next Y78.36%
EPS Next 2Y51.7%
EPS Next 3Y28.33%
EPS Next 5Y28.81%
Revenue Next Year43.72%
Revenue Next 2Y40.92%
Revenue Next 3Y26.6%
Revenue Next 5Y26.47%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 30.27, AKBA can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, AKBA is valued cheaply inside the industry as 91.04% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of AKBA to the average of the S&P500 Index (22.80), we can say AKBA is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 30.27
AKBA Price Earnings VS Forward Price EarningsAKBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AKBA is valued cheaply inside the industry as 92.32% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 31.24
AKBA Per share dataAKBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AKBA's earnings are expected to grow with 28.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.7%
EPS Next 3Y28.33%

More info and screens

0

5. Dividend

5.1 Amount

AKBA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (8/27/2025, 8:00:01 PM)

After market: 3.0394 +0.03 (+0.98%)

3.01

-0.08 (-2.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners35.93%
Inst Owner Change12.08%
Ins Owners3.61%
Ins Owner Change1.02%
Market Cap798.10M
Analysts87.27
Price Target7.55 (150.83%)
Short Float %10.01%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)132.68%
Min EPS beat(2)100%
Max EPS beat(2)165.36%
EPS beat(4)2
Avg EPS beat(4)47%
Min EPS beat(4)-54.81%
Max EPS beat(4)165.36%
EPS beat(8)5
Avg EPS beat(8)38.39%
EPS beat(12)7
Avg EPS beat(12)14.69%
EPS beat(16)8
Avg EPS beat(16)19.03%
Revenue beat(2)2
Avg Revenue beat(2)27.45%
Min Revenue beat(2)25.24%
Max Revenue beat(2)29.66%
Revenue beat(4)3
Avg Revenue beat(4)14.85%
Min Revenue beat(4)-17.55%
Max Revenue beat(4)29.66%
Revenue beat(8)3
Avg Revenue beat(8)0.04%
Revenue beat(12)5
Avg Revenue beat(12)-0.56%
Revenue beat(16)8
Avg Revenue beat(16)11.67%
PT rev (1m)0%
PT rev (3m)0.34%
EPS NQ rev (1m)-17.19%
EPS NQ rev (3m)-25%
EPS NY rev (1m)-9.37%
EPS NY rev (3m)58.33%
Revenue NQ rev (1m)4.42%
Revenue NQ rev (3m)1.63%
Revenue NY rev (1m)8.95%
Revenue NY rev (3m)13.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 30.27
P/S 3.92
P/FCF N/A
P/OCF N/A
P/B 27.31
P/tB N/A
EV/EBITDA 31.24
EPS(TTM)-0.17
EYN/A
EPS(NY)0.1
Fwd EY3.3%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.77
BVpS0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.56%
ROE -124.84%
ROCE 1.76%
ROIC 1.39%
ROICexc 3.52%
ROICexgc 10.33%
OM 1.96%
PM (TTM) N/A
GM 83.22%
FCFM N/A
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Debt/EBITDA 2.02
Cap/Depr 0.76%
Cap/Sales 0.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.98
Quick Ratio 1.84
Altman-Z -4.19
F-Score5
WACC9.96%
ROIC/WACC0.14
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y78.36%
EPS Next 2Y51.7%
EPS Next 3Y28.33%
EPS Next 5Y28.81%
Revenue 1Y (TTM)16.79%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%43.13%
Revenue Next Year43.72%
Revenue Next 2Y40.92%
Revenue Next 3Y26.6%
Revenue Next 5Y26.47%
EBIT growth 1Y111.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y92.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.09%
OCF growth 3YN/A
OCF growth 5YN/A